The Department of Veterans Affairs (VA) and Department of Defense (DoD) Clinical Practice Guidelines (CPGs) are developed and updated based on the best information available at the time of publication and are designed to provide information to educate and aid healthcare teams in clinical decision making. Type 2 Diabetes Mellitus (T2DM) Disorder has an overall estimated prevalence of 6.1% in the general population and between 4 -17% in Service Members. T2DM is a highly prevalent disease, both within military and veteran populations. Globally, a marked increase has occurred in T2DM from approximately 151 million in 2000 to 537 million individuals in 2021 the number of Americans diagnosed with T2DM in 2022 has followed a similar trend. There are approximately 29 million people diagnosed, and approximately 8.5 million undiagnosed individuals, impacting 11.3% of the United States (US) population of which about 13% are adults. In the Military Health System (MHS), the prevalence of diagnosed DM ranged from 7.3–11.2% in 2006 and from 8.3–13.6% in 2010. This CPG intends to promote evidence-based management of T2DM, improving quality of care and patient outcomes. The CPG is designed to assist primary care clinicians using a patient-centric approach in determination of appropriate treatment and individualized delivery of patient care. The Department of Veterans Affairs/Department of Defense (VA/DoD) Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included an interdisciplinary panel of practicing clinician experts. The clinician experts developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated published clinical literature through April 11, 2022. Recommendations are based on a systematic review of the scientific evidence, weighing the benefits and harms of interventions, consideration of what is known about patient values and preferences, and the application of the evidence across demographic groups and settings. Recommendations are made through evidence review, informed by 12 key questions, by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Four decision domains are used to determine strength and direction of each recommendation: confidence in the quality of evidence, balance of desirable and undesirable outcomes, values and preferences, and other implications, as appropriate (e.g., resource use). T2DM is a major contributor to morbidity and mortality in the US. It is associated with a two-fold to four-fold increased risk for atherosclerotic cardiovascular disease, resulting in substantial morbidity and mortality from coronary events. T2DM reduces the health and well-being of active-duty service members, veterans, and their families. This poster presentation summarizes key features of the CPG: the appropriate diagnosis of T2DM, target treatment goals, algorithms, and nonpharmacologic and pharmacologic treatments.